Hosie G, Bird H
Clinical Pharmacology Unit (Rheumatism Research), Chapel Allerton Hospital, Leeds, UK.
Eur J Rheumatol Inflamm. 1994;14(4):21-8.
Musculoskeletal disorders such as soft tissue injuries have traditionally been treated with oral NSAIDs, despite the significant side-effects associated with their clinical use. However, four separate multicentre, double-blind, double-dummy clinical trials have shown that the efficacy of the topical NSAID, felbinac, is equivalent to that of the oral NSAID, ibuprofen, in the treatment of soft tissue injuries, and to that of oral ibuprofen or fenbufen in mild to moderate osteoarthritis. In general practice the incidence of side-effects with felbinac is low, while oral NSAIDs have been associated with significant problems, particularly in the gastrointestinal system. Consequently, the cost of treating side-effects is reduced with felbinac treatment compared with oral NSAIDs, making it a logical treatment alternative from an economic view point as well as for reasons of efficacy and safety.
尽管口服非甾体抗炎药在临床使用中存在显著副作用，但诸如软组织损伤等肌肉骨骼疾病传统上一直使用口服非甾体抗炎药进行治疗。然而，四项独立的多中心、双盲、双模拟临床试验表明，局部用非甾体抗炎药氟比洛芬在治疗软组织损伤方面的疗效与口服非甾体抗炎药布洛芬相当，在治疗轻至中度骨关节炎方面与口服布洛芬或芬布芬相当。在一般医疗实践中，氟比洛芬的副作用发生率较低，而口服非甾体抗炎药则存在重大问题，尤其是在胃肠道系统。因此，与口服非甾体抗炎药相比，使用氟比洛芬治疗可降低副作用的治疗成本，从经济角度以及疗效和安全性方面来看，它都是一种合理的治疗选择。
